News and Trends 29 Mar 2019
Galapagos Nears First Drug Approval with Phase III Success in Rheumatoid Arthritis
Galapagos has released positive data from two phase III trials testing its flagship drug candidate, filgotinib, that will let the company and its partner Gilead apply for marketing approval. 20 years after its foundation, Galapagos is finally approaching the finish line. Yesterday, the company has shared positive data from two clinical trials that together enrolled […]